2022
Delayed presentation of HIV among older individuals: a growing problem
Justice AC, Goetz MB, Stewart CN, Hogan BC, Humes E, Luz PM, Castilho JL, Nash D, Brazier E, Musick B, Yiannoutsos C, Malateste K, Jaquet A, Cornell M, Shamu T, Rajasuriar R, Jiamsakul A, Althoff KN. Delayed presentation of HIV among older individuals: a growing problem. The Lancet HIV 2022, 9: e269-e280. PMID: 35218732, PMCID: PMC9128643, DOI: 10.1016/s2352-3018(22)00003-0.Peer-Reviewed Original ResearchConceptsLate presentationOlder individualsInternational epidemiology DatabasesAssociation of agePresentation of HIVElectronic medical recordsProportion of peopleEpidemiology DatabaseHIV infectionAIDS (IeDEA) consortiumMedical recordsEffective treatmentAge groupsOlder agePresentationAgeIndividualsHIVInfectionCarePrevention
2021
HIV Infection and the Risk of World Health Organization–Defined Sudden Cardiac Death
Freiberg MS, Duncan MS, Alcorn C, Chang C, Kundu S, Mumpuni A, Smith EK, Loch S, Bedigian A, Vittinghoff E, So‐Armah K, Hsue PY, Justice AC, Tseng ZH. HIV Infection and the Risk of World Health Organization–Defined Sudden Cardiac Death. Journal Of The American Heart Association 2021, 10: e021268. PMID: 34493058, PMCID: PMC8649505, DOI: 10.1161/jaha.121.021268.Peer-Reviewed Original ResearchConceptsHIV viral loadCD4 cell countFirst clinical visitHIV infectionViral loadSCD riskCell countWorld Health OrganizationCopies/Elevated HIV viral loadLow CD4 cell countsSudden cardiac death rateVeterans Aging Cohort StudyCox proportional hazards regressionHealth OrganizationConclusions HIV infectionSCD risk factorsCardiac death rateAging Cohort StudyProportional hazards regressionSudden cardiac deathCells/Mean baseline ageRace/ethnicityCohort studyCD4+ cell count and outcomes among HIV-infected compared with uninfected medical ICU survivors in a national cohort
Akgün KM, Krishnan S, Butt AA, Gibert CL, Graber CJ, Huang L, Pisani MA, Rodriguez-Barradas MC, Hoo GWS, Justice AC, Crothers K, Tate JP. CD4+ cell count and outcomes among HIV-infected compared with uninfected medical ICU survivors in a national cohort. AIDS 2021, 35: 2355-2365. PMID: 34261095, PMCID: PMC8563390, DOI: 10.1097/qad.0000000000003019.Peer-Reviewed Original ResearchMeSH KeywordsCD4 Lymphocyte CountCohort StudiesHIV InfectionsHumansIntensive Care UnitsSurvivorsVeteransTrends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015
Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Re V, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Network Open 2021, 4: e2037512. PMID: 33595662, PMCID: PMC7890526, DOI: 10.1001/jamanetworkopen.2020.37512.Peer-Reviewed Original ResearchConceptsHCC incidence ratesHigher HCC riskHepatitis C virusHepatitis B virusModern cART eraCD4 cell countIncidence rateCART eraHCC riskHepatocellular carcinomaCohort studyTriple infectionNorth American AIDS Cohort CollaborationCell countAvailable CD4 cell countHigher HIV RNA levelsLow CD4 cell countsCombination antiretroviral therapy eraDiagnosis of HCCAnti-HCV seropositivityAntiretroviral therapy eraHBV-HCV coinfectionRecent HIV RNAHIV RNA levelsHBV e antigen
2020
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018
Lee J, Humes E, Hogan B, Buchacz K, Eron J, Gill M, Sterling T, Rebeiro P, Lima V, Mayor A, Silverberg M, Horberg M, Moore R, Althoff K, Benson C, Bosch R, Emory-Grady G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Johns R, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Crouzat F, Loutfy M, Smith G, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Hunter-Mellado R, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, Park L, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. Clinical Infectious Diseases 2020, 73: e2334-e2337. PMID: 33383586, PMCID: PMC8492212, DOI: 10.1093/cid/ciaa1904.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountHIVHIV InfectionsHumansPrescriptionsUnited StatesTiming of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus
Silverberg MJ, Leyden W, Hernández-Ramírez RU, Qin L, Lin H, Justice AC, Hessol NA, Achenbach CJ, D’Souza G, Engels EA, Althoff KN, Mayor AM, Sterling TR, Kitahata MM, Bosch RJ, Saag MS, Rabkin CS, Horberg MA, Gill MJ, Grover S, Mathews WC, Li J, Crane HM, Gange SJ, Lau B, Moore RD, Dubrow R, Neugebauer RS. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clinical Infectious Diseases 2020, 72: 1900-1909. PMID: 32785640, PMCID: PMC8315132, DOI: 10.1093/cid/ciaa1046.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeCD4 Lymphocyte CountHIVHIV InfectionsHumansNeoplasmsSarcoma, KaposiConceptsVirus-related cancersEarly antiretroviral therapyHuman immunodeficiency virusAntiretroviral therapyART initiationImmunodeficiency virusNorth American AIDS Cohort CollaborationART-naive PLWHEarly ART initiationAntiretroviral therapy initiationHIV transmission riskNon-Hodgkin lymphomaCancer registry linkageRisk of cancerMarginal structural modelsRace/ethnicityCohort CollaborationTherapy initiationChart reviewIncident cancerRegistry linkageViral hepatitisTime-dependent confoundingCancer groupViral etiologyT Lymphocyte Subsets Associated With Prevalent Diabetes in Veterans With and Without Human Immunodeficiency Virus
Bailin SS, McGinnis KA, McDonnell WJ, So-Armah K, Wellons M, Tracy RP, Doyle MF, Mallal S, Justice AC, Freiberg MS, Landay AL, Wanjalla C, Koethe JR. T Lymphocyte Subsets Associated With Prevalent Diabetes in Veterans With and Without Human Immunodeficiency Virus. The Journal Of Infectious Diseases 2020, 222: 252-262. PMID: 32052044, PMCID: PMC7323499, DOI: 10.1093/infdis/jiaa069.Peer-Reviewed Original ResearchConceptsT cell subsetsT cellsMemory CD4Prevalent diabetesMemory T cell expansionVeterans Aging Cohort StudyMultivariable logistic regression modelHuman immunodeficiency virus (HIV) populationPrevalent diabetes casesPrevalent diabetes mellitusChronic immune activationHIV-negative individualsHIV-negative participantsT lymphocyte subsetsPrevalence of diabetesTraditional risk factorsAging Cohort StudyHuman immunodeficiency virusT cell expansionLogistic regression modelsCytomegalovirus serostatusLymphocyte subsetsCohort studyDiabetes mellitusHIV status
2019
Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada
Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Hessol NA, Achenbach CJ, Brooks JT, Gill MJ, Grover S, Horberg MA, Li J, Mathews WC, Mayor AM, Patel P, Rabkin CS, Rachlis A, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R, Benson C, Bosch R, Kirk G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Moore R, Moore R, Rodriguez B, Horberg M, Silverberg M, Thorne J, Rabkin C, Margolick J, Jacobson L, D’Souza G, Klein M, Kroch A, Burchell A, Betts A, Lindsay J, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Mathews W, Eron J, Napravnik S, Kitahata M, Crane H, Drozd D, Sterling T, Haas D, Rebeiro P, Turner M, Justice A, Dubrow R, Fiellin D, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, Althoff K, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Freeman A, Kitahata M, Van Rompaey S, Crane H, Drozd D, Morton L, McReynolds J, Lober W, Gange S, Althoff K, Lee J, You B, Hogan B, Zhang J, Jing J, Humes E, Coburn S. Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clinical Infectious Diseases 2019, 70: 1176-1185. PMID: 31044245, PMCID: PMC7319056, DOI: 10.1093/cid/ciz329.Peer-Reviewed Original ResearchMeSH KeywordsAnus NeoplasmsCanadaCD4 Lymphocyte CountHIVHIV InfectionsHumansImmunosuppression TherapyUnited StatesViral LoadViremiaConceptsAnal cancer riskHIV RNA measuresCancer riskPeak CD4North American AIDS Cohort CollaborationRNA measuresHIV-1 RNA levelsHuman immunodeficiency virus (HIV) viremiaOncogenic human papillomavirus (HPV) infectionAnal cancer developmentAssociation of immunosuppressionTime-updated CD4T-cell countsHuman papillomavirus infectionHuman immunodeficiency virusCohort CollaborationPapillomavirus infectionImmunodeficiency virusImmunoregulatory controlCD4Cox modelCancer promotionUseful markerCancer developmentRNA levelsImproved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals
Tate JP, Sterne JAC, Justice AC. Improved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals. AIDS 2019, Publish Ahead of Print: &na;. PMID: 30649058, PMCID: PMC6749990, DOI: 10.1097/qad.0000000000002140.Peer-Reviewed Original ResearchConceptsWhite blood countC-statisticBlood countVeterans Aging Cohort Study (VACS) IndexAntiretroviral Therapy Cohort CollaborationDiscrimination of mortalityVACS Index 2.0Antiretroviral therapy initiationCD4 cell countHIV-positive populationHarrell's C-statisticHIV-1 RNAHIV-positive individualsKaplan-Meier plotsCohort CollaborationNadir CD4VAC patientsAntiretroviral therapyCause mortalityCD8 ratioTherapy initiationViral suppressionGeneral healthExcess mortalityLaboratory valuesEmulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals
Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández‐Díaz S, Meyer L, Seng R, Drozd DR, Seage G, Bonnet F, Le Marec F, Moore RD, Reiss P, Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals. Statistics In Medicine 2019, 38: 2428-2446. PMID: 30883859, PMCID: PMC6499640, DOI: 10.1002/sim.8120.Peer-Reviewed Original ResearchConceptsHIV-positive individualsCopies/First-line treatment regimenAIDS Research NetworkAIDS-free survivalCells/Integrated Clinical SystemsHIV-CAUSAL CollaborationOutcomes of interestRisk difference estimatesDirect effectAntiretroviral therapyHIV RNACD4 thresholdTreatment regimenNew regimenTreatment strategiesHIV researchTarget trialsRegimenTherapyResearch NetworkTrialsSurvivalClinical systemsAssociation of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study
Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Achenbach CJ, Hessol NA, D'Souza G, Gebo KA, Gill MJ, Grover S, Horberg MA, Li J, Mathews WC, Mayor AM, Park LS, Rabkin CS, Salters K, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R, AIDS N, Betts A, Brooks J, Freeman A, Van Rompaey S, Burchell A, Yip B, You B, Hogan B, Grasso C, Hogg R, Benson C, Drozd D, Sterling T, Haas D, Humes E, Crane H, Willig J, Eron J, Martin J, Saag M, Jing J, Zhang J, Lindsay J, Hunter-Mellado R, Deeks S, Zhu J, Montaner J, McReynolds J, Gabler K, Buchacz K, Rodriguez B, Thorne J, Margolick J, Anastos K, Jacobson L, Klein M, Kroch A, Morton L, Turner M, Fiellin D, Gange S, Mugavero M, Harrigan P, Rebeiro P, Bosch R, Kirk G, Mayer K, McKaig R, Coburn S, Napravnik S, Kitahata M, Lober W, Lee J. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. The Lancet HIV 2019, 6: e240-e249. PMID: 30826282, PMCID: PMC6531288, DOI: 10.1016/s2352-3018(18)30360-6.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaRecent CD4 countCD4 countHIV viraemiaKey independent predictorsViral loadIndependent predictorsNorth American AIDS Cohort CollaborationCNS non-Hodgkin's lymphomaOverall non-Hodgkin lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaAssociation of immunosuppressionMulticentre cohort studyNon-Hodgkin lymphoma (NHL) riskAverage viral loadUS Health ResourcesB-cell lymphomaOverall immune functionB cell activationLong-term careCohort CollaborationRecent immunosuppressionAntiretroviral therapyCohort study
2018
Gender and alcohol use
Matson TE, McGinnis KA, Rubinsky AD, Frost MC, Czarnogorski M, Bryant KJ, Edelman EJ, Satre DD, Catz SL, Bensley KM, Fiellin DA, Justice AC, Williams EC. Gender and alcohol use. AIDS 2018, 32: 2247-2253. PMID: 30005010, PMCID: PMC6136970, DOI: 10.1097/qad.0000000000001946.Peer-Reviewed Original ResearchConceptsAlcohol useHIV careViral suppressionART treatmentVeterans Aging Cohort Study (VACS) dataVeterans Health Administration patientsAUDIT-C alcoholHIV medical careHIV care continuumLarge national cohortCohort study dataPoisson regression modelsPrescribed ARTPrevalence of engagementRetrospective cohortNational cohortUS veteransWorse outcomesCare continuumRelative riskStratified analysisMedical careHIVGender modifiesWomenEfficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatientsBenefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/&mgr;l
Kong CY, Sigel K, Criss SD, Sheehan DF, Triplette M, Silverberg MJ, Henschke CI, Justice A, Braithwaite RS, Wisnivesky J, Crothers K. Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/&mgr;l. AIDS 2018, 32: 1333-1342. PMID: 29683843, PMCID: PMC5991188, DOI: 10.1097/qad.0000000000001818.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancer screeningCD4 cell countMedicaid Services criteriaCancer screeningLung cancerMortality reductionCell countLDCT examinationsAnnual low-dose computed tomographyUninfected individualsLung cancer mortality reductionVeterans Aging Cohort StudyCancer mortality reductionAntiretroviral therapy adherenceAging Cohort StudyLung cancer mortalityCells/Lung Cancer Policy ModelMultiple national organizationsAlternative screening strategiesBase-case analysisHIV cohortCohort studyFormer smokersRecent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV
Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, Horberg MA, Bosch RJ, Eyawo O, Palella FJ. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 62-72. PMID: 29419568, PMCID: PMC5889316, DOI: 10.1097/qai.0000000000001642.Peer-Reviewed Original ResearchConceptsFramingham risk scoreEffect of abacavirMyocardial infarctionHazard ratioHepatitis C virus infectionType 1Type 2 myocardial infarctionCrude hazard ratioC virus infectionIncident myocardial infarctionInjection drug useHistory of AIDSUse increases riskMarginal structural modelsCohort CollaborationLow CD4Antiretroviral therapyKidney functionMI outcomesTime-dependent confoundingRisk factorsMI occurrenceVirus infectionIncrease riskRisk scoreAssociation of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease
Beckman JA, Duncan MS, Alcorn CW, So-Armah K, Butt AA, Goetz M, Tindle HA, Sico J, Tracy RP, Justice AC, Freiberg MS. Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease. Circulation 2018, 138: 255-265. PMID: 29535090, PMCID: PMC6050082, DOI: 10.1161/circulationaha.117.032647.Peer-Reviewed Original ResearchConceptsRisk of PADIncident PAD eventsPeripheral artery diseaseHuman immunodeficiency virusCD4 cell countTraditional atherosclerotic risk factorsPAD risk factorsAtherosclerotic risk factorsPAD eventsRisk factorsCell countUninfected veteransCD4 cellsArtery diseaseHIV infectionHIV statusViral loadCells/Peripheral artery disease eventsPrior peripheral artery diseaseHuman immunodeficiency virus (HIV) infectionVeterans Aging Cohort StudyHIV-1 ribonucleic acidHIV infection statusHIV viral load
2017
Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older
Lodi S, Costagliola D, Sabin C, del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 76: 311-318. PMID: 28746165, PMCID: PMC5704899, DOI: 10.1097/qai.0000000000001498.Peer-Reviewed Original ResearchConceptsGeneral HIV populationImmediate initiationHIV populationCD4 countCells/US veteransAIDS mortalityAIDS-free individualsNon-AIDS mortalityUS Veteran cohortHIV-positive individualsHIV-CAUSAL CollaborationAntiretroviral therapyCause mortalityAntiretroviral treatmentMedian ageClinical guidelinesVeteran cohortHigh mortalityMortalityCD4Younger participantsRiskBaselineVeteransIncreased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population
Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, Burkholder GA, Mathews WC, Silverberg MJ, Sterling TR, Heckbert SR, Budoff MJ, Van Rompaey S, Delaney JAC, Wong C, Tong W, Palella FJ, Elion RA, Martin JN, Brooks JT, Jacobson LP, Eron JJ, Justice AC, Freiberg MS, Klein DB, Post WS, Saag MS, Moore RD, Crane HM. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 568-576. PMID: 28520615, PMCID: PMC5522001, DOI: 10.1097/qai.0000000000001450.Peer-Reviewed Original ResearchConceptsTraditional CVD risk factorsDetectable HIV RNACVD risk factorsIncidence rateRisk factorsCD4 countHIV RNAMyocardial infarctionCardiovascular diseaseNorth American AIDS Cohort CollaborationType 1 myocardial infarctionHIV-specific factorsLow CD4 countSuppressive antiretroviral treatmentIncidence rate ratiosCohort CollaborationIncident MINA-ACCORDAggressive managementAntiretroviral treatmentMultivariable analysisAtherosclerosis RiskMI riskCommunity cohortGeneral populationAssociation of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada
Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, Althoff KN, Achenbach CJ, Hessol NA, Modur SP, D'Souza G, Bosch RJ, Grover S, Horberg MA, Kitahata MM, Mayor AM, Novak RM, Rabkin CS, Sterling TR, Goedert JJ, Justice AC, Engels EA, Moore RD, Silverberg MJ. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 382-390. PMID: 28394855, PMCID: PMC5490794, DOI: 10.1097/qai.0000000000001394.Peer-Reviewed Original ResearchConceptsT-cell countsKS riskCD4 countKaposi's sarcomaART useHIV-1 RNA viral loadNorth American AIDS Cohort CollaborationTime-updated Cox regressionCD4 T-cell countKaposi's sarcoma riskAntiretroviral therapy useRNA viral loadRecent CD4 countViral load measuresAssociation of CD4Cohort CollaborationKS etiologyRecent VLVL measuresAntiretroviral therapyHIV diagnosisIndependent predictorsTherapy useViral loadCox regressionSurvival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Collaboration T, Trickey A, May M, Vehreschild J, Obel N, Gill M, Crane H, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice A, Sterling T, Ingle S, Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 2017, 4: e349-e356. PMID: 28501495, PMCID: PMC5555438, DOI: 10.1016/s2352-3018(17)30066-8.Peer-Reviewed Original ResearchConceptsInitiation of ARTAntiretroviral therapyART initiationCause mortalityHazard ratioLife expectancyCalendar periodCause-specific mortality hazard ratiosYears of ARTFirst yearHIV-1 cohortToxic antiretroviral drugsCombination antiretroviral therapyHIV-positive patientsCD4 cell countManagement of comorbiditiesMortality hazard ratioUK Medical Research CouncilHealth care plannersMedical Research CouncilEDCTP2 programmeCohort studyViral loadAntiretroviral drugsYear survival